Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | R547 |
Synonyms | |
Therapy Description |
R547 is a small molecule that selectively inhibits cyclin-dependent kinases, leading to cell cycle arrest and apoptosis in cancer cells (PMID: 17121911, PMID: 32123493). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
R547 | R-547|R 547|RO 4584820|RO4584820 | CDK1 Inhibitor 13 CDK2 Inhibitor 31 CDK4 Inhibitor 17 | R547 is a small molecule that selectively inhibits cyclin-dependent kinases, leading to cell cycle arrest and apoptosis in cancer cells (PMID: 17121911, PMID: 32123493). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RB1 wild-type TP53 wild-type | colon carcinoma | sensitive | R547 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911). | 17121911 |
RB1 wild-type TP53 wild-type | mantle cell lymphoma | sensitive | R547 | Preclinical | Actionable | In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911). | 17121911 |
RB1 mut TP53 mut | cervical cancer | sensitive | R547 | Preclinical | Actionable | In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911). | 17121911 |
RB1 wild-type TP53 wild-type | lung carcinoma | sensitive | R547 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911). | 17121911 |
RB1 wild-type TP53 mut | mantle cell lymphoma | sensitive | R547 | Preclinical | Actionable | In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911). | 17121911 |
RB1 wild-type TP53 mut | breast carcinoma | sensitive | R547 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911). | 17121911 |
RB1 wild-type TP53 wild-type | melanoma | sensitive | R547 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911). | 17121911 |
RB1 mut TP53 mut | breast carcinoma | sensitive | R547 | Preclinical | Actionable | In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911). | 17121911 |
RB1 wild-type TP53 wild-type | breast carcinoma | sensitive | R547 | Preclinical | Actionable | In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911). | 17121911 |
RB1 wild-type TP53 mut | colon carcinoma | sensitive | R547 | Preclinical | Actionable | In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911). | 17121911 |
RB1 mut TP53 mut | prostate carcinoma | sensitive | R547 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911). | 17121911 |
RB1 wild-type TP53 mut | osteosarcoma | sensitive | R547 | Preclinical | Actionable | In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911). | 17121911 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|